The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.
Open accessAbstract
Plasminogen activator inhibitor-1 (PAI-1), a rapid inhibitor of tissue-type plasminogen activator, has been shown to be an independent risk factor for recurrent myocardial infarction (MI) at a young age. To investigate whether genetic variation in the PAI-1 gene is affecting plasma PAI-1 levels, a sample of 145 patients with an MI before the age of 45 years was genotyped for two polymorphisms at the PAI-1 locus, together with a sample of 95 healthy individuals of a similar age. All individuals were measured for plasma PAI-1 levels as well as for other fibrinolytic and metabolic risk indicators. A HindIII restriction fragment length polymorphism (RFLP) was used in this study in conjunction with a previously unreported eight-allele dinucleotide repeat polymorphism at the PAI-1 locus. The dinucleotide repeat polymorphism and HindIII RFLP were in strong linkage disequilibrium. There was no difference in the frequency of alleles of either polymorphism between patient and control groups. However, the smaller dinucleotide repeat alleles were significantly associated (p = 0.03) with higher plasma PAI-1 levels in the patient sample. This association was also apparent in the control sample but not at significant levels. Differences in regression coefficients for the effect of triglycerides on plasma PAI-1 levels suggest that triglyceride regulation of PAI-1 is genotype specific. Our data suggest that genetic variation at this locus contributes to between-individual differences in the level of plasma PAI-1, which is important in fibrinolysis and the pathogenesis of MI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,887
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
[21] Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction
Mullis, K. B., & Faloona, F. A. (1987) · Methods in Enzymology · doi:10.1016/0076-6879(87)55023-6 · Cited by 5,694
Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction.
Weber, J. L., & May, P. E. (1989) · Europe PMC (PubMed Central) · Cited by 3,399
Immunoassay of insulin with insulin-antibody precipitate
HALES, C., & RANDLE, P. (1963) · Biochemical Journal · doi:10.1042/bj0880137 · Cited by 2,638
USE OF GLUCOSE OXIDASE, PEROXIDASE, AND O-DIANISIDINE IN DETERMINATION OF BLOOD AND URINARY GLUCOSE
Huggett, A. S. G., & Nixon, D. A. (1957) · The Lancet · doi:10.1016/s0140-6736(57)92595-3 · Cited by 1,802
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., Faire, U., Dahlén, G., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Self-citationHamsten, A., Wiman, B., de Faire, U., & Blombäck, M. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512193132501 · Cited by 1,342
Self-citation(1985) · PubMed · Cited by 706
Evidence for a rapid inhibitor to tissue plasminogen activator in plasma
Chmielewska, J., Rånby, M., & Wiman, B. (1983) · Thrombosis Research · doi:10.1016/0049-3848(83)90407-3 · Cited by 469
Self-citation
Cited by
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Packard, R. R. S., & Libby, P. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.097360 · Cited by 925
Plasminogen-Activator Inhibitor Type 1 and Coronary Artery Disease
Kohler, H. P., & Grant, P. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422406 · Cited by 806
Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
Lane, D. A., & Grant, P. J. (2000) · Blood · doi:10.1182/blood.v95.5.1517.005k48_1517_1532 · Cited by 495
Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
Ridker, P. M., Brown, N. J., Vaughan, D. E., Harrison, D. G., & Mehta, J. L. (2004) · Circulation · doi:10.1161/01.cir.0000133444.17867.56 · Cited by 422
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi, M.-C., & Juhan-Vague, I. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000242905.41404.68 · Cited by 390
Metadata
- Authors
- Dawson, S., Hamsten, A., Wiman, B., Henney, A., & Humphries, S.
- Venue
- Arteriosclerosis and Thrombosis: A Journal of Vascular Biology
- Published
- 1991-01
- Volume
- 11
- Issue
- 1
- Pages
- 183-190
- ISSN
- 1049-8834 (ISSN-L)
- OpenAlex
- W2116284648
- Cited by
- 318
- References
- 36
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. https://app.cochat.ai/papers/10.1161/01.atv.11.1.183
- The paper
- Dawson, S., Hamsten, A., Wiman, B., Henney, A., & Humphries, S. (1991). Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology. https://doi.org/10.1161/01.atv.11.1.183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.